Security key
221015100
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)
CUSIP: 221015100
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 30,026,264
- Total 13F value
- $158,538,176
- Share change
- +2,389,593
- Put/Call ratio
- 7.9%
- SEC-reported price per share
- $5.28
- Number of holders
- 61
- Value change
- +$12,733,385
- Number of buys
- 34
- Number of sells
- 12
- Shares outstanding
- 84,335,427
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
61
Top holders
10
CRVS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Corvus Pharmaceuticals, Inc. SEC filings
Corvus Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 221015100
Recent filing periods:
Ownership snapshot
Top reported holders of CRVS - Corvus Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F
3/4/5
Lead comparable stake: 8.2%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 8.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
8.2%
SAMLYN CAPITAL, LLC
7.3%
Point72 Asset Management, L.P.
7.1%
ADAMS STREET PARTNERS LLC
3.9%
VANGUARD GROUP INC
2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
8.2%
|
$12,637,450
6,943,654 shares
|
— | 30 Jun 2024 |
| SAMLYN CAPITAL, LLC |
13F
Company
|
7.3%
|
$11,143,898
6,123,021 shares
|
— | 30 Jun 2024 |
| Point72 Asset Management, L.P. |
13F
Company
|
7.1%
|
$10,855,408
5,964,510 shares
|
— | 30 Jun 2024 |
| ADAMS STREET PARTNERS LLC |
13F
3/4/5
Company · 10%+ Owner
|
3.9%
|
$5,961,621
3,275,616 shares
|
— | 30 Jun 2024 |
| VANGUARD GROUP INC |
13F
Company
|
2%
|
$3,003,910
1,650,500 shares
|
— | 30 Jun 2024 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.67%
|
$1,026,356
563,932 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
61
Shares
30,026,264
Rows available
61
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
46
Q3 2024 holders
61
Holder diff
15
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend